College of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
School of Medicine, Indiana University, Indianapolis, IN, USA.
Support Care Cancer. 2021 Nov;29(11):6201-6209. doi: 10.1007/s00520-021-06173-1. Epub 2021 Apr 6.
Literature supporting the efficacy of complementary and integrative medicine (CIM) alongside radiotherapy is fragmented with varying outcomes and levels of evidence. This review summarizes the available evidence on CIM used with radiotherapy in order to inform clinicians.
A systematic literature review identified studies on the use of CIM during radiotherapy. Inclusion required the following criteria: the study was interventional, CIM therapy was for human patients with cancer, and CIM therapy was administered concurrently with radiotherapy. Data points of interest were collected from included studies. A subset was identified as high-quality using the Jadad scale. Fisher's exact test was used to assess the association between study results, outcome measured, and type of CIM.
Overall, 163 articles met inclusion. Of these, 68 (41.7%) were considered high-quality trials. Articles published per year increased over time (p < 0.01). Frequently identified therapies were biologically based therapies (47.9%), mind-body therapies (23.3%), and alternative medical systems (13.5%). Within the subset of high-quality trials, 60.0% of studies reported a favorable change with CIM while 40.0% reported no change. No studies reported an unfavorable change. Commonly assessed outcome types were patient-reported (41.1%) and provider-reported (21.5%). Rate of favorable change did not differ based on type of CIM (p = 0.90) or outcome measured (p = 0.24).
Concurrent CIM may reduce radiotherapy-induced toxicities and improve quality of life, suggesting that physicians should discuss CIM with patients receiving radiotherapy. This review provides a broad overview of investigations on CIM use during radiotherapy and can inform how radiation oncologists advise their patients about CIM.
支持补充和整合医学(CIM)与放射治疗联合应用的文献分散且结果各异,证据水平也不同。本综述总结了 CIM 与放射治疗联合应用的现有证据,以便为临床医生提供信息。
系统文献检索确定了关于放射治疗期间使用 CIM 的研究。纳入标准为:研究为干预性研究,CIM 治疗针对癌症人类患者,CIM 治疗与放射治疗同时进行。从纳入的研究中收集感兴趣的数据点。使用 Jadad 量表确定了一个亚组为高质量研究。Fisher 精确检验用于评估研究结果、测量的结果和 CIM 类型之间的关联。
共有 163 篇文章符合纳入标准。其中,68 篇(41.7%)被认为是高质量试验。每年发表的文章数量随时间增加(p<0.01)。经常被识别的疗法是基于生物学的疗法(47.9%)、身心疗法(23.3%)和替代医学系统(13.5%)。在高质量试验的子集中,60.0%的研究报告 CIM 有有利的变化,而 40.0%的研究报告没有变化。没有研究报告不利的变化。通常评估的结果类型是患者报告(41.1%)和提供者报告(21.5%)。有利变化的发生率与 CIM 类型(p=0.90)或测量的结果(p=0.24)无关。
同期 CIM 可能减少放射治疗引起的毒性并提高生活质量,这表明医生应在接受放射治疗的患者中讨论 CIM。本综述提供了 CIM 在放射治疗期间使用的广泛调查概述,并为放射肿瘤学家如何为患者提供 CIM 咨询提供信息。